mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical University10.21886/2219-8075-2015-1-21-26mvjr-185Research ArticleОБЗОРЫREVIEWЛЕЧЕНИЕ ОЖИРЕНИЯ: ИСТОРИЯ ВЗЛЕТОВ И ПАДЕНИЙTREATMENT FOR OBESITY: THE HISTORY OF FLIGHTS&FALLSВолковаН. И.VolkovaN. I.dim3.rostgmu@gmail.comПоркшеянМ. И.PorksheyanM. I.ГюльмагомедоваА. Н.GyulmagomedovaA. N.Ростовский государственный медицинский университет, Кафедра внутренних болезней с основами общей физиотерапии № 3РоссияRostov State Medical University, Department of internal medicine with the basis of general physiotherapyRussian Federation201530032015012126Copyright © Волкова Н.И., Поркшеян М.И., Гюльмагомедова А.Н., 20152015Волкова Н.И., Поркшеян М.И., Гюльмагомедова А.Н.Volkova N.I., Porksheyan M.I., Gyulmagomedova A.N.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/185

В статье представлен литературный обзор, посвященный некоторым историческим аспектам медикаментозного лечения ожирения, и описаны перспективы развития новых препаратов.

Th is article is a literary review that is generally devoted to some historical aspects of medicinal treatment for obesity and described prospect of development of new preparations.

ожирениелечениебурая жировая ткань.obesitytreatmentbrown adipose tissue.ReferencesPutnam J.J. Cases of myxoedema and acromegalia treated with benefi t by sheep’s thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of Grave’s disease and acromegalia // Am J Med Sci. 1983.106: 125–148.Putnam J.J. Cases of myxoedema and acromegalia treated with benefi t by sheep’s thyroids: recent observations respecting the pathology of the cachexias following disease of the thyroid; clinical relationships of Grave’s disease and acromegalia // Am J Med Sci. 1983.106: 125–148.DuBois E.F. Basal metabolism in health and disease. Lea and Febiger, Philadelphia, 1924.DuBois E.F. Basal metabolism in health and disease. Lea and Febiger, Philadelphia, 1924.Bray G.A., Melvin K.E.W., Chopra I.J. Eff ect of triiodothyronine on some metabolic responses of obese patients //Am J Clin Nutr. 1973. 26: 715–721.Bray G.A., Melvin K.E.W., Chopra I.J. Eff ect of triiodothyronine on some metabolic responses of obese patients //Am J Clin Nutr. 1973. 26: 715–721.Ravussin E., Lillioja S., Anderson T.E., Christin L., Bogardus C. Determinants of 24-hour energy expenditure in man: methods and results using a respiratory chamber //J Clin Invest. 1986.78:1568–1578.Ravussin E., Lillioja S., Anderson T.E., Christin L., Bogardus C. Determinants of 24-hour energy expenditure in man: methods and results using a respiratory chamber //J Clin Invest. 1986.78:1568–1578.Ehrlich P, Hata SюDie experimentelle Chemotherapie der Spirillosen. Julius Springer, Berlin, 1910.Ehrlich P, Hata SюDie experimentelle Chemotherapie der Spirillosen. Julius Springer, Berlin, 1910.Simkins S. Dinitrophenol and desiccated thyroid in the treatment of obesity: a comprehensive clinical and laboratory study // JAMA. 1937. 108: 2110–2193.Simkins S. Dinitrophenol and desiccated thyroid in the treatment of obesity: a comprehensive clinical and laboratory study // JAMA. 1937. 108: 2110–2193.Nathanson M.H. Th e central action of beta-aminopropylbenzene (Benzedrine) //JAMA. 1937. 108: 528–531.Nathanson M.H. Th e central action of beta-aminopropylbenzene (Benzedrine) //JAMA. 1937. 108: 528–531.Davidoff E., Reifenstein E.C. Jr. Th e stimulating action of benzedrine sulfate: a comparative study of the responses of normal persons and of depressed patients // JAMA. 1937.108: 1770–1776.Davidoff E., Reifenstein E.C. Jr. Th e stimulating action of benzedrine sulfate: a comparative study of the responses of normal persons and of depressed patients // JAMA. 1937.108: 1770–1776.Ulrich H. Narcolepsy and its treatment with benzedrine sulfate // N EngI J Med. 1937.217(18): 696–701.Ulrich H. Narcolepsy and its treatment with benzedrine sulfate // N EngI J Med. 1937.217(18): 696–701.Lesses M.F., Myerson A. Human autonomic pharmacology XVI: benzedrine sulfate as an aid in the treatment of obesity //N Engl J Med. 1938.218: 119–124.Lesses M.F., Myerson A. Human autonomic pharmacology XVI: benzedrine sulfate as an aid in the treatment of obesity //N Engl J Med. 1938.218: 119–124.Leibowitz S.F., Rossakis C. Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol //Eur Pharm. 1978.53: 69–81.Leibowitz S.F., Rossakis C. Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol //Eur Pharm. 1978.53: 69–81.Weintraub M. Long-term weight control, the National Heart, Lung and Blood Institute funded multimodal intervention study //Clin Pharmacol Th er. 1992.51(5): 581–585.Weintraub M. Long-term weight control, the National Heart, Lung and Blood Institute funded multimodal intervention study //Clin Pharmacol Th er. 1992.51(5): 581–585.FDA letter to manufacturers of drug products containing Phenylpropanolamine (PPA) dated 11/03/2000.FDA letter to manufacturers of drug products containing Phenylpropanolamine (PPA) dated 11/03/2000.Derosa G., Maffi oli P. Anti-obesity drugs: a review about their eff ects and their safety // Expert Opin. Drug Saf. 2012. 11(3): 459–471.Derosa G., Maffi oli P. Anti-obesity drugs: a review about their eff ects and their safety // Expert Opin. Drug Saf. 2012. 11(3): 459–471.Luque C.A., Rey A.J. Th e discovery and status of sibutramine as an anti-obesity drug //European Journal of Pharmacology. 2002. 440:119–128.Luque C.A., Rey A.J. Th e discovery and status of sibutramine as an anti-obesity drug //European Journal of Pharmacology. 2002. 440:119–128.James W.P.T., Caterson I.D., Coutinho W et al. for the SCOUT Investigators. Eff ect of sibutramine on cardiovascular outcomes in overweight and obese subjects //N Engl J Med. 2010. 363:905–17.James W.P.T., Caterson I.D., Coutinho W et al. for the SCOUT Investigators. Eff ect of sibutramine on cardiovascular outcomes in overweight and obese subjects //N Engl J Med. 2010. 363:905–17.European Medicines Agency recommends suspension of marketing authorisations for sibutramine. Press release of the European Medicines Agency, London, January 21, 2010 [Electronic resource] // EMA[Offi cial website]. Feb. 2015.http:// www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf(дата обращения: 24.02.2015).European Medicines Agency recommends suspension of marketing authorisations for sibutramine. Press release of the European Medicines Agency, London, January 21, 2010 [Electronic resource] // EMA[Offi cial website]. Feb. 2015.http:// www.ema.europa.eu/pdfs/human/referral/sibutramine/3940810en.pdf(дата обращения: 24.02.2015).Kirkham T.C. Cannabinoids and appetite: food craving and food pleasure //Int Rev Psychiatry. 2009. 21(2): 163–71.Kirkham T.C. Cannabinoids and appetite: food craving and food pleasure //Int Rev Psychiatry. 2009. 21(2): 163–71.Rang & Dales Pharmacology. Obesity. Elsevier. 2015.Rang & Dales Pharmacology. Obesity. Elsevier. 2015.Plieth J. Obesity: what next aft er the CB1 antagonists’ failure // Scrip 2008.3411/3412: 44–47.Plieth J. Obesity: what next aft er the CB1 antagonists’ failure // Scrip 2008.3411/3412: 44–47.Rodgers R.J., Tschop M.H., Wilding J.P.H. Anti-obesity drugs: past, present and future //Dis Model Mech. 2012. 5(5): 621–626.Rodgers R.J., Tschop M.H., Wilding J.P.H. Anti-obesity drugs: past, present and future //Dis Model Mech. 2012. 5(5): 621–626.Obesity drugs approved [Electronic resource] // FDA [Offi cial website]. Feb. 2015.www.fda.gov(дата обращения: 24.02.2015).Obesity drugs approved [Electronic resource] // FDA [Offi cial website]. Feb. 2015.www.fda.gov(дата обращения: 24.02.2015).Под редакцией Дедова И.И.(Волкова Н.И.)Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 2011.Под редакцией Дедова И.И.(Волкова Н.И.)Национальные клинические рекомендации по лечению морбидного ожирения у взрослых. 2011.

The authors declare that there are no conflicts of interest present.